Analytical Data
-
Gene name
CDKN2A
- Application
-
Alternative Names
P16; ARF; CDK4I; CMM2; INK4; INK4a; MLM; MTS1; TP16; P14; P14ARF; P16INK4a; P19; Melanoma P16; Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P42771
-
Expression Region
Ser8~Asp156
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CDKN2A gene, located on chromosome 9, plays a critical role in cell cycle regulation by encoding two proteins, p16^INK4a and p14^ARF, both of which are crucial for tumor suppression. Mutations and deletions in CDKN2A are frequently observed in various cancers, including melanoma, pancreatic cancer, and lung cancer, highlighting its significance as a tumor suppressor. Recent studies have shown that recombinant proteins derived from CDKN2A, particularly p16^INK4a, can be utilized in therapeutic applications and cancer diagnostics. By producing CDKN2A recombinant proteins in laboratory settings, researchers can investigate their interactions with cyclin-dependent kinases and other cell cycle regulators, paving the way for new cancer treatments. Additionally, such proteins have potential applications in the development of vaccines and other immunotherapeutic strategies aimed at enhancing anti-tumor immunity. Understanding the structural and functional properties of CDKN2A recombinant proteins is essential for elucidating their role in oncogenesis and for designing effective interventions. Therefore, ongoing research in this area continues to refine and expand our knowledge of CDKN2A's implications in cancer biology, potentially leading to novel strategies for targeting this important pathway in cancer treatment and prevention.
